SFRP2 and pancreatic neoplasm: CRISPR–Cas9-based genome editing provides a new therapeutic strategy with high specificity [41], such as the dCas9-multiGCN4/scFv-TET1CD-sgRNA-based SFRP2-targeted demethylation system provides a SFRP2-targeting therapeutic strategy to inhibit pancreatic tumor metastasis [42].